Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma has disclosed EBITDA across 7 years of filings, most recently posting -$12.0 million for Q4 2025.

• EBITDA for Q4 2025 came in at -$12.0 million, down 69.74% year-over-year; the trailing twelve-month figure through Dec 2025 was -$44.3 million (down 109.46% YoY), and the FY2025 annual result was -$37.9 million, down 73.58% from the prior year.
• EBITDA came in at -$12.0 million for Q4 2025 at Benitec Biopharma, down from -$8.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2022 to a low of -$14.5 million in Q1 2025.
• The 5-year median for EBITDA is -$4.8 million (2021), against an average of -$6.2 million.
• Across the five-year window, EBITDA grew 12.6% in 2024 and sank 249.09% in 2025, its largest moves.
• Benitec Biopharma's EBITDA stood at -$4.9 million in 2021, then dropped by 14.21% to -$5.6 million in 2022, then retreated by 25.11% to -$7.0 million in 2023, then declined by 1.18% to -$7.1 million in 2024, then tumbled by 69.74% to -$12.0 million in 2025.
• The last three EBITDA figures came in at -$12.0 million (Q4 2025), -$8.9 million (Q3 2025), and -$8.9 million (Q2 2025), per Business Quant data.